Pheochromocytoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(33 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Pheochromocytoma}}
{{Pheochromocytoma}}
{{CMG}}
{{CMG}} {{AE}} {{AAM}} {{MAD}}


==Overview==
==Overview==
Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated [[catecholamines]] and [[metanephrine]] levels
Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated 24-hour urinary fractionated [[catecholamines]] and [[metanephrine]]<nowiki/>s for low-risk patients and [[plasma]] fractionated [[Metanephrine|metanephrines]] for high-risk patients.
 
==Laboratory Findings==
==Laboratory Findings==
The diagnosis can be established by measuring [[catecholamine]]s and [[metanephrine]]s in plasma or through a 24-hour urine collection. Urinary [[vanillyl mandelic acid]] may be elevated.
An elevated concentration of the following is diagnostic of [[pheochromocytoma]].
* Elevated 24-hour urine fractionated metanephrines and catecholamines. The cutoff values are: <ref name="pmid12574179">{{cite journal| author=Sawka AM, Jaeschke R, Singh RJ, Young WF| title=A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. | journal=J Clin Endocrinol Metab | year= 2003 | volume= 88 | issue= 2 | pages= 553-8 | pmid=12574179 | doi=10.1210/jc.2002-021251 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12574179  }}</ref>
** [[Normetanephrine]] >900 mcg/24 hours
** [[Metanephrine]] >400 mcg/24 hours
** [[Norepinephrine]] >170 mcg/24 hours
** [[Epinephrine]] >35 mcg/24 hours
** [[Dopamine]] >700 mcg/24 hours
* Elevated plasma fractionated metanephrines. The cutoff values are:
** Metanephrine > 0.3-0.5 nmol/L
** Normetanephrine > 0.66- 0.9 nmol/L <ref name="pmid7778821">{{cite journal| author=Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC | display-authors=etal| title=Plasma metanephrines in the diagnosis of pheochromocytoma. | journal=Ann Intern Med | year= 1995 | volume= 123 | issue= 2 | pages= 101-9 | pmid=7778821 | doi=10.7326/0003-4819-123-2-199507150-00004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7778821  }} </ref> <ref name="pmid8849581">{{cite journal| author=Pattarino F, Bouloux PM| title=The diagnosis of malignancy in phaeochromocytoma. | journal=Clin Endocrinol (Oxf) | year= 1996 | volume= 44 | issue= 2 | pages= 239-41 | pmid=8849581 | doi=10.1046/j.1365-2265.1996.657475.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8849581  }} </ref>
 
* Elevated urinary [[vanillyl mandelic acid]] <ref name="pmid11903030">{{cite journal| author=Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P et al.| title=Biochemical diagnosis of pheochromocytoma: which test is best? | journal=JAMA | year= 2002 | volume= 287 | issue= 11 | pages= 1427-34 | pmid=11903030 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11903030  }}</ref> <ref name="pmid7778821">{{cite journal| author=Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC et al.| title=Plasma metanephrines in the diagnosis of pheochromocytoma. | journal=Ann Intern Med | year= 1995 | volume= 123 | issue= 2 | pages= 101-9 | pmid=7778821 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7778821  }}</ref>
 
The following drugs interfere with [[urinary]] [[catecholamines]] metabolism and shoudl be discontinued two weeks before any [[hormonal]] assessments: <ref name="pmid171215182">{{cite journal| author=Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER et al.| title=Phaeochromocytoma, new genes and screening strategies. | journal=Clin Endocrinol (Oxf) | year= 2006 | volume= 65 | issue= 6 | pages= 699-705 | pmid=17121518 | doi=10.1111/j.1365-2265.2006.02714.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17121518  }}</ref>
* Tricyclic antidepressants (TCAs)
* Levodopa
* Antipsychotics
* Ethanol
* Acetaminophen
* Phenoxybenzamine <ref name="pmid14557417">{{cite journal| author=Kudva YC, Sawka AM, Young WF| title=Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. | journal=J Clin Endocrinol Metab | year= 2003 | volume= 88 | issue= 10 | pages= 4533-9 | pmid=14557417 | doi=10.1210/jc.2003-030720 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14557417  }} </ref>
 
Patients with spells of elevated [[blood pressure]] (sudden onset of a [[symptom]] or [[symptoms]]) can be negative in-between spells and should be tested directly after the attacks.<ref name="pmid7630214">{{cite journal| author=Young WF, Maddox DE| title=Spells: in search of a cause. | journal=Mayo Clin Proc | year= 1995 | volume= 70 | issue= 8 | pages= 757-65 | pmid=7630214 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7630214  }}</ref>
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Endocrinology]]
[[Category:Endocrinology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 21:44, 28 July 2020

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma laboratory findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma laboratory findings

CDC on Pheochromocytoma laboratory findings

Pheochromocytoma laboratory findings in the news

Blogs on Pheochromocytoma laboratory findings

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated 24-hour urinary fractionated catecholamines and metanephrines for low-risk patients and plasma fractionated metanephrines for high-risk patients.

Laboratory Findings

An elevated concentration of the following is diagnostic of pheochromocytoma.

  • Elevated 24-hour urine fractionated metanephrines and catecholamines. The cutoff values are: [1]
  • Elevated plasma fractionated metanephrines. The cutoff values are:
    • Metanephrine > 0.3-0.5 nmol/L
    • Normetanephrine > 0.66- 0.9 nmol/L [2] [3]

The following drugs interfere with urinary catecholamines metabolism and shoudl be discontinued two weeks before any hormonal assessments: [5]

  • Tricyclic antidepressants (TCAs)
  • Levodopa
  • Antipsychotics
  • Ethanol
  • Acetaminophen
  • Phenoxybenzamine [6]

Patients with spells of elevated blood pressure (sudden onset of a symptom or symptoms) can be negative in-between spells and should be tested directly after the attacks.[7]

References

  1. ↑ Sawka AM, Jaeschke R, Singh RJ, Young WF (2003). "A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines". J Clin Endocrinol Metab. 88 (2): 553–8. doi:10.1210/jc.2002-021251. PMID 12574179.
  2. ↑ 2.0 2.1 Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC; et al. (1995). "Plasma metanephrines in the diagnosis of pheochromocytoma". Ann Intern Med. 123 (2): 101–9. doi:10.7326/0003-4819-123-2-199507150-00004. PMID 7778821.
  3. ↑ Pattarino F, Bouloux PM (1996). "The diagnosis of malignancy in phaeochromocytoma". Clin Endocrinol (Oxf). 44 (2): 239–41. doi:10.1046/j.1365-2265.1996.657475.x. PMID 8849581.
  4. ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
  5. ↑ Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER; et al. (2006). "Phaeochromocytoma, new genes and screening strategies". Clin Endocrinol (Oxf). 65 (6): 699–705. doi:10.1111/j.1365-2265.2006.02714.x. PMID 17121518.
  6. ↑ Kudva YC, Sawka AM, Young WF (2003). "Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience". J Clin Endocrinol Metab. 88 (10): 4533–9. doi:10.1210/jc.2003-030720. PMID 14557417.
  7. ↑ Young WF, Maddox DE (1995). "Spells: in search of a cause". Mayo Clin Proc. 70 (8): 757–65. PMID 7630214.
Retrieved from "https://www.wikidoc.org/index.php?title=Pheochromocytoma_laboratory_findings&oldid=1633652"